RxDoctor Payments Data

Benjamin Currie, MD

Ophthalmology · Holland, MINPI 1538457130

Payments from drug & device makers

$7,900in general payments, 2019–2025

Across 56 payments — averaging $141.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$7K
  • Lensar, Inc.$261
  • Alcon$142
  • Rayner Intraocular Lenses Limited$117
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$115
  • Regeneron Healthcare Solutions, Inc.$109
  • plus $475 from 12 others

What the payments were for

  • Speaking & faculty fees$262%
  • Food & beverage$1,34998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,900 in reported general payments places this provider in the 85th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$384,311
Medicare patients
221
Services billed
2,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate121$6,405
Latanoprost303$5,708
VyzultaLatanoprostene Bunod11$5,551
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat120$3,058
BromsiteBromfenac Sodium11$2,680
Bromfenac Sodium15$2,451
ValacyclovirValacyclovir Hcl31$1,976
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$1,101
Timolol Maleate60$918
Ketorolac Tromethamine31$677
Brimonidine Tartrate48$617
Acyclovir13$165
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim20$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$56$5,55111 claims
Sun Pharmaceutical Industries Inc.Bromsite$38$2,68011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →